false
0001433607
0001433607
2026-11-20
2026-11-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): November 20, 2026
InspireMD,
Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
| 001-35731 |
|
26-2123838 |
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
6303
Waterford District Drive, Suite 215
Miami, Florida |
|
33126 |
| (Address of Principal Executive
Offices) |
|
(Zip Code) |
(888)
776-6804
(Registrant’s
Telephone Number, Including Area Code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common Stock, par value
$0.0001 per share |
|
NSPR |
|
The Nasdaq Capital Market
LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Events.
As
previously disclosed, on November 16, 2026, InspireMD, Inc. (the “Company”) closed its previously announced offering
of (i) 7,342,308 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and
pre-funded warrants to purchase up to 50,350,000 shares of Common Stock, and (ii) accompanying Series L warrants to purchase up to 43,269,231
shares of Common Stock (the “Common Warrants”), pursuant to the Company’s effective automatic shelf registration
statement on Form S-3 (File No. 333-286309) previously filed with the Securities and Exchange Commission (the “SEC”),
raising approximately $34.9 million in net proceeds after deducting underwriting discounts and before offering expenses. Pursuant to
the Underwriting Agreement, dated November 13, 2026 (the “Underwriting Agreement”), by and among the Company and Lake
Street Capital Markets, LLC, as representative (the “Representative”) of the several underwriters named therein (collectively,
the “Underwriters”), the Underwriters were granted a 30-day option (the “Option”) to purchase up
to an additional 8,635,846 shares of Common Stock (the “Option Shares”) and/or Common Warrants to purchase up to 6,490,384
shares of Common Stock (the “Option Common Warrants”) from the Company on the same terms and conditions.
On
November 18, 2026, the Representative notified the Company that it had elected to exercise the Option in full. The offering of the Option
Shares and Option Common Warrants closed on November 20, 2026, raising an additional approximately $5.3 million in net proceeds after
deducting underwriting discounts and before offering expenses.
The Option Common Warrants
will be issued pursuant to a warrant agency agreement, dated as of November 12, 2026, by and between the Company and Securities Transfer
Corporation, as warrant agent.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
INSPIREMD,
INC. |
| |
|
| Date: November 20, 2026 |
By: |
/s/
Marvin Slosman |
| |
Name: |
Marvin Slosman |
| |
Title: |
Chief Executive Officer |